Vancouver, BC, April 9, 2020--ImaginAb Inc., a leading clinical stage immuno-oncology imaging company, and Vancouver-based ARTMS Products Inc., a global leader in the development of novel technologies which enable the production of the world's most-used diagnostic imaging isotopes, announced they have entered a multi-year non-exclusive partnership to explore a novel radiochemistry manufacture of ImaginAb's lead asset 89Zr CD8 ImmunoPET.
|